🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 32384F105
- Market Cap
- Mid Cap
- IPO
- 10/7/2015 · $12.00/share
Business: CytomX Therapeutics, Inc. develops Probody therapeutics for the treatment of cancer. Probodies are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.
Company Contact
- CEO
- Sean A. McCarthy
- VPF
- Christopher W. Ogden
- Headquarters
- 151 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080
- Phone
- 650-515-3185
- Fax
- 650-351-0353
- Investor Relations
- Stephanie Ascher · 212-362-1200 · stephanie.ascher@sternir.com